MedTrace Logo

Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease

NCT00633841 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-10-19

No results posted yet for this study

Summary

The purpose of this study is to assess the tolerability and safety of repeated subcutaneous injection of a single dose of AFFITOPE AD02 in patients with mild to moderate Alzheimer's Disease.

Conditions

Interventions

BIOLOGICAL

AFFITOPE AD02

4 subcutaneous injections of IP in 4-week intervals

Sponsors & Collaborators

  • Affiris AG

    lead INDUSTRY

Principal Investigators

  • Margot Schmitz, Univ. Doz. Dr. · Ordination Univ. Doz. Dr. Margot Schmitz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00633841 on ClinicalTrials.gov